DESTINY-Breast03 Phase 3 Study Results

Patient Populations and Disposition ESMO BC 2022 #165 Mini Oral Enrollment Assessed for eligibility (n=17) Accrued (n=15) Excluded (n=2) + Not meeting inclusion criteria (n=2) Treatment Received trastuzumab-deruxctecan (n=15) Follow-Up Discontinued trastuzumab-deruxtecan (n=9) • Discontinuation due to progression (n=3) + Discontinuation for reasons other than progression (n=6) Analysis Intention-to-treat population (n=15) Evaluable for analysis of BM response (n=14) * Excluded from analysis due to absence of BM (n=1) Safety population (n=15) Daiichi-Sankyo 53

View entire presentation